Preclinical comparison of superpulse thulium fiber laser and a holmium:YAG laser for lithotripsy.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 15 02 2019
accepted: 25 04 2019
pubmed: 6 5 2019
medline: 15 12 2020
entrez: 6 5 2019
Statut: ppublish

Résumé

A superpulse (500 W peak power) thulium fiber laser operating at a 1940 nm wavelength, suitable for lithotripsy, has recently been developed. The goal of this study was to compare stone fragmentation and dusting performance of the prototype superpulse thulium fiber laser with leading commercially available, high-power holmium:YAG lithotripters (wavelength 2100 nm) in a controlled in vitro environment. Two experimental setups were designed for investigating stone ablation rates and retropulsion effects, respectively. In addition, the ablation setup enabled water temperature measurements during stone fragmentation in the laser-stone interaction zone. Human uric acid (UA) and calcium oxalate monohydrate (COM) stones were used for ablation experiments, whereas standard BegoStone phantoms were utilized in retropulsion experiments. The laser settings were matched in terms of pulse energy, pulse repetition rate, and average power. At equivalent settings, thulium fiber laser ablation rates were higher than those for holmium:YAG laser in both dusting mode (threefold for COM stones and 2.5-fold for UA stones) and fragmentation mode (twofold for UA stones). For single-pulse retropulsion experiments, the threshold for onset of stone retropulsion was two to four times higher for thulium fiber laser. The holmium:YAG laser generated significantly stronger retropulsion effects at equal pulse energies. The water temperature elevation near the laser-illuminated volume did not differ between the two lasers. Distinctive features of the thulium fiber laser (optimal wavelength and long pulse duration) resulted in faster stone ablation and lower retropulsion in comparison to the holmium:YAG laser.

Identifiants

pubmed: 31055626
doi: 10.1007/s00345-019-02785-9
pii: 10.1007/s00345-019-02785-9
doi:

Substances chimiques

Thulium 8RKC5ATI4P
Holmium W1XX32SQN1

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

497-503

Références

Front Surg. 2017 Sep 29;4:57
pubmed: 29067287
Curr Urol Rep. 2014 Apr;15(4):397
pubmed: 24532341
BJU Int. 1999 Jul;84(1):1-9
pubmed: 10444114
Eur Urol. 2016 Jul;70(1):188-194
pubmed: 27086502
Urologiia. 2018 Mar;(1):112-120
pubmed: 29634144
Eur Urol. 2004 Jan;45(1):58-64
pubmed: 14667517
J Urol. 1998 Aug;160(2):471-6
pubmed: 9679900
J Endourol. 2017 Mar;31(3):272-277
pubmed: 27960541
Lasers Surg Med. 2002;30(3):184-90
pubmed: 11891737
J Endourol. 2010 Jul;24(7):1135-40
pubmed: 20575700
BJU Int. 2014 Aug;114(2):261-7
pubmed: 24219145
J Biomed Opt. 2011 Jul;16(7):071403
pubmed: 21806249
Appl Opt. 1973 Mar 1;12(3):555-63
pubmed: 20125343
J Urol. 2002 May;167(5):1972-6
pubmed: 11956420
J Urol. 2012 Mar;187(3):914-9
pubmed: 22264464
Lasers Surg Med. 2019 Aug;51(6):522-530
pubmed: 30648761
J Endourol. 2017 Jun;31(6):598-604
pubmed: 28340540
Nat Rev Urol. 2018 Sep;15(9):563-573
pubmed: 29884804
J Urol. 1998 Jan;159(1):17-23
pubmed: 9400428
J Urol. 2003 Mar;169(3):881-5
pubmed: 12576805

Auteurs

Viktoria Andreeva (V)

NTO "IRE-POLUS", One Vvedenskogo Sq, Fryazino, Moscow Region, 141120, Russia.

Andrey Vinarov (A)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Ilya Yaroslavsky (I)

IPG Medical, 377 Simarano Dr, Marlborough, MA, 01752, USA. iyaroslavsky@ipgmedical.com.

Anastasia Kovalenko (A)

NTO "IRE-POLUS", One Vvedenskogo Sq, Fryazino, Moscow Region, 141120, Russia.

Alexander Vybornov (A)

IPG Medical, 377 Simarano Dr, Marlborough, MA, 01752, USA.

Leonid Rapoport (L)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Dmitry Enikeev (D)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Nikolay Sorokin (N)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Alim Dymov (A)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Dmitry Tsarichenko (D)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Petr Glybochko (P)

Institute for Urology and Reproductive Health, Sechenov University, 19 Bolshaya Pirogovskaya Ul, Moscow, 119146, Russia.

Nathaniel Fried (N)

Department of Physics and Optical Science, University of North Carolina Charlotte, 9201 University City Boulevard, Charlotte, NC, 28223, USA.

Olivier Traxer (O)

University Pierre et Marie Curie Paris VI, 4 Place Jussieu, 75005, Paris, France.

Gregory Altshuler (G)

IPG Medical, 377 Simarano Dr, Marlborough, MA, 01752, USA.

Valentin Gapontsev (V)

IPG Photonics, 50 Old Webster Rd, Oxford, MA, 01540, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH